A317690 Stock Overview
Operates as an in-vitro diagnostics company in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
QuantaMatrix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,050.00 |
| 52 Week High | ₩23,700.00 |
| 52 Week Low | ₩3,360.00 |
| Beta | 0.16 |
| 11 Month Change | -16.55% |
| 3 Month Change | -52.10% |
| 1 Year Change | 27.77% |
| 33 Year Change | -45.25% |
| 5 Year Change | n/a |
| Change since IPO | -74.90% |
Recent News & Updates
Shareholder Returns
| A317690 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.0% | -8.1% | 2.9% |
| 1Y | 27.8% | 18.1% | -2.8% |
Return vs Industry: A317690 exceeded the KR Biotechs industry which returned 21.1% over the past year.
Return vs Market: A317690 exceeded the KR Market which returned -4% over the past year.
Price Volatility
| A317690 volatility | |
|---|---|
| A317690 Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A317690's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A317690's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 92 | Sung Hoon Kwon | www.quantamatrix.com |
QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. The company was founded in 2010 and is based in Seoul, South Korea.
QuantaMatrix Inc. Fundamentals Summary
| A317690 fundamental statistics | |
|---|---|
| Market cap | ₩100.05b |
| Earnings (TTM) | -₩17.94b |
| Revenue (TTM) | ₩3.60b |
27.8x
P/S Ratio-5.6x
P/E RatioIs A317690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A317690 income statement (TTM) | |
|---|---|
| Revenue | ₩3.60b |
| Cost of Revenue | ₩2.55b |
| Gross Profit | ₩1.06b |
| Other Expenses | ₩19.00b |
| Earnings | -₩17.94b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09k |
| Gross Margin | 29.27% |
| Net Profit Margin | -497.76% |
| Debt/Equity Ratio | 155.9% |
How did A317690 perform over the long term?
See historical performance and comparison